Protara Therapeutics (TARA) Stock: Buy, Sell, or Hold?
TARA - Protara Therapeutics, Inc. Common Stock
$2.70
-0.06 (-2.17%)
▼
5d:
-17.68%
30d:
-31.47%
90d:
-33.82%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 09, 2026
Get Alerted When TARA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: TARA is down 17.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: TARA is down 17.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: TARA is currently trading at $2.70, which is considered oversold relative to its 30-day fair value range of $3.28 to $3.99.
Technical Outlook: Technically, TARA is in a downtrend. The price is currently testing key support at $2.62. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TARA scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $25.71 (+852.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TARA is in a downtrend. The price is currently testing key support at $2.62. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TARA scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $25.71 (+852.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.28 -
$3.99
Company Quality Score
38/100
(SELL)
Volume Confirmation
MODERATE
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: Trading 852.4% below Wall St target ($25.71)
- WARNING: Composite score 38/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.28 -
$3.99
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.62
Resistance Level
$3.88
Current Trend
Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.60
Wall Street Target
$25.71
(+852.4%)
Share & Embed Analysis
Last updated: October 03, 2026 4:32 AM ET
Data refreshes hourly during market hours. Next update: 5:32 AM
Data refreshes hourly during market hours. Next update: 5:32 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TARA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Jacqueline Zummo
SELL
1134 shares
2026-04-08
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$84 | 71 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$75 | 60 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$28 | 53 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 58 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$95 | 57 HOLD |
